Thomas Sandgaard Sells 2,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.09, for a total value of $18,180.00. Following the transaction, the chief executive officer now directly owns 14,609,662 shares of the company’s stock, valued at approximately $132,801,827.58. The trade was a 0.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 13th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.37, for a total value of $16,740.00.
• On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.77, for a total transaction of $17,540.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Price Performance

Shares of NASDAQ:ZYXI opened at $8.09 on Friday. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77. The company has a market cap of $257.67 million, a P/E ratio of 53.93 and a beta of 0.53. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The company’s fifty day moving average is $8.23 and its two-hundred day moving average is $8.92.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Equities analysts expect that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zynex

A number of hedge funds have recently modified their holdings of ZYXI. Gladius Capital Management LP grew its stake in Zynex by 53.4% in the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after purchasing an additional 1,742 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after buying an additional 1,846 shares during the last quarter. Cim LLC raised its position in Zynex by 6.1% during the second quarter. Cim LLC now owns 43,581 shares of the company’s stock valued at $406,000 after acquiring an additional 2,508 shares in the last quarter. American Century Companies Inc. lifted its stake in Zynex by 10.1% in the second quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock valued at $290,000 after acquiring an additional 2,864 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Zynex by 1.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock worth $1,797,000 after purchasing an additional 2,954 shares during the last quarter. 29.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ZYXI shares. Royal Bank of Canada cut their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright raised their target price on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, October 25th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.